IGEA Pharma N.V. / Key word(s): Delisting/Delisting
04-Aug-2023 / 22:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
IGEA to update on SIX decision
Hoofddorp, the Netherlands, 4 August 2023. IGEA Pharma N.V. (SIX: IGPH) today announced the intention to appeal the decision of the SIX to delist the company.
The new board of directors entered in charge by end of April 2023 acted immediately to grant continuation of the activities and to respect any publication deadline, but the situation of carelessness left by the previous management did not allow to further shorten times. The board disclosed the 2022 annual report by end of July 2022, in compliance with the extension of terms requested to the SIX on May 2023. The decision of the SIX does furthermore not considerwhat the board effectively did since entrance into office and until disclosure of the annual report 2022 and is therefore prejudicial to the continuation of the activities of the company. IGEA, together with its lawyers, will therefore appeal against the decision of SIX to delist the company.
IGEA Pharma N.V. focuses on CBD and other valuable vegetable extractions for health prevention, cosmeceuticaland other selected industries.Furthermore, IGEA operates on preventative health-tech products and devices, commercializing an Alzheimer’s prevention set (which includes ’Alz1’, an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded ‘Alz1 Tab’ designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in the next future.
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl
Pierpaolo Cerani, CEO,firstname.lastname@example.org
This document constitutes neither an offer to buy nor to subscribe securities and either this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development, or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as maybe required by law.
End of Inside Information
|Company:||IGEA Pharma N.V.|
|2123 WT Hoofddorp|
|Phone:||+31 23 568 9494|
|Listed:||Regulated Unofficial Market in Frankfurt; SIX Swiss Exchange|
|EQS News ID:||1696793|
|End of Announcement||EQS News Service|